PE20090607A1 - Formulacion farmaceutica de dispersion liposomal en polvo seco - Google Patents

Formulacion farmaceutica de dispersion liposomal en polvo seco

Info

Publication number
PE20090607A1
PE20090607A1 PE2008001429A PE2008001429A PE20090607A1 PE 20090607 A1 PE20090607 A1 PE 20090607A1 PE 2008001429 A PE2008001429 A PE 2008001429A PE 2008001429 A PE2008001429 A PE 2008001429A PE 20090607 A1 PE20090607 A1 PE 20090607A1
Authority
PE
Peru
Prior art keywords
inhibitor
caspasa
dry powder
pharmaceutical formulation
antabidor4
Prior art date
Application number
PE2008001429A
Other languages
English (en)
Inventor
Fadi Eskandar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40149638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090607A1 publication Critical patent/PE20090607A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA O MAS SUSTANCIAS MEDICAMENTOSAS SELECCIONADAS DE AGONISTA DEL ADRENORECEPTOR -BETA2, ANTAGONISTA MUSCARINICO, GLUCOCORTICOSTEROIDE, INHIBIDOR DE CASPASA, ANTAGONISTA LTB4, INHIBIDOR DE FOSFODIESTERASA, ENTRE OTROS; B) UN LIPIDO SELECCIONADO DE DIMARSETOIL, FOSAFATIDILCOLINA, LECITINA DE SOJA, DIPALMITOIL FOSFATIDILCOLINA, ENTRE OTROS; C) UN COLIPIDO SELECCIONADO DE FOSFATIDILCOLINA PEGILADA, COLESTEROL; D) MEJORADOR DE FLUJO TAL COMO MALTOSA, MANITOL, INULINA, SACAROSA, LACTOSA, DEXTROSA, ENTRE OTROS. DICHA FORMULACION DITRIBUYE SUSTANCIAS MEDICAMENTOSAS MEDIANTE LA ENCAPSULACION LIPOSOMAL AUMENTANDO LA EFICIENCIA DE ATRAPAMIENTO DEL INGREDIENTE ACTIVO FARMACEUTICO
PE2008001429A 2007-08-24 2008-08-22 Formulacion farmaceutica de dispersion liposomal en polvo seco PE20090607A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114981 2007-08-24
EP07123163 2007-12-13

Publications (1)

Publication Number Publication Date
PE20090607A1 true PE20090607A1 (es) 2009-06-11

Family

ID=40149638

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001429A PE20090607A1 (es) 2007-08-24 2008-08-22 Formulacion farmaceutica de dispersion liposomal en polvo seco

Country Status (5)

Country Link
AR (1) AR067997A1 (es)
CL (1) CL2008002479A1 (es)
PE (1) PE20090607A1 (es)
TW (1) TW200916126A (es)
WO (1) WO2009027337A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
CN104394846B (zh) 2012-05-03 2018-10-19 爱尔兰詹森科学公司 用于治疗上呼吸道感染的聚肌苷酸-聚胞苷酸（聚(i:c)）配制品
WO2018160295A1 (en) * 2017-01-25 2018-09-07 Yiannios James John Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
AU2019215127A1 (en) 2018-02-01 2020-06-18 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
EP3520782A3 (en) * 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
AU2019380294A1 (en) * 2018-11-13 2021-05-27 Civitas Therapeutics, Inc. Respirable polynucleotide powder formulations for inhalation
WO2021004524A1 (en) * 2019-07-10 2021-01-14 The University Of Hong Kong PEGylated synthetic KL4 peptide, Compositions and Methods Thereof
CN114209651A (zh) * 2021-11-18 2022-03-22 上海欣峰制药有限公司 头孢噻肟钠化合物的药物制剂及其制备方法
CN114053226A (zh) * 2021-11-18 2022-02-18 上海欣峰制药有限公司 头孢米诺钠化合物的药物制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004787A1 (en) * 1995-08-01 1997-02-13 Novartis Ag Liposomal oligonucleotide compositions
EP2664672A1 (en) * 2003-04-17 2013-11-20 Alnylam Pharmaceuticals Inc. Modified iRNA agents
JPWO2005011632A1 (ja) * 2003-08-01 2006-09-14 独立行政法人産業技術総合研究所 糖鎖を有する標的指向性および腸管吸収制御性リポソームならびにそれを含む癌治療薬および診断薬
SI1771206T1 (en) * 2004-05-05 2018-06-29 Silence Therapeutics Gmbh LIPID LIPID COMPLEXES AND THEIR USE
GB0418172D0 (en) * 2004-08-13 2004-09-15 Ic Vec Ltd Vector
WO2006080118A1 (ja) * 2005-01-28 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. 標的遺伝子の発現を抑制する組成物
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
JP2009534342A (ja) * 2006-04-20 2009-09-24 サイレンス・セラピューティクス・アーゲー 血管内皮に特異的に送達するためのリポプレックス処方剤
GB0608838D0 (en) * 2006-05-04 2006-06-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2009027337A1 (en) 2009-03-05
TW200916126A (en) 2009-04-16
AR067997A1 (es) 2009-10-28
CL2008002479A1 (es) 2009-05-08

Similar Documents

Publication Publication Date Title
PE20090607A1 (es) Formulacion farmaceutica de dispersion liposomal en polvo seco
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
WO2009088414A3 (en) Oral pharmaceutical dosage forms
TR201909461T4 (tr) Si̇stemi̇k olarak etki̇ eden akti̇f maddeleri̇ i̇çeren parazi̇ti̇si̇dal oral veteri̇nerli̇ğe ai̇t bi̇leşi̇mler, bunlarin yöntemleri̇ ve kullanimlari
AR051969A1 (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
CR20110110A (es) Composicion farmaceutica
SV2009003231A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
WO2010021607A3 (en) Pharmaceutical formulation
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
MX361372B (es) Formulacion farmaceutica disponible por via oral adecuada para manejo mejorado de trastornos del movimiento.
NI201100154A (es) Métodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento, prevención y manejo de la tuberculosis
WO2008128191A3 (en) Oral cephalotaxine dosage forms
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
EP3453702A3 (en) Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones

Legal Events

Date Code Title Description
FX Voluntary withdrawal